Portage Biotech Inc. Files Form 6-K for Registration Statement
Ticker: ATON · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration-statement, corporate-action
TL;DR
Portage Biotech filed a 6-K, incorporating it into their S-8. Nothing new, just housekeeping.
AI Summary
Portage Biotech Inc. filed a Form 6-K on January 6, 2025, to be incorporated by reference into its Form S-8 registration statement (File No. 333-275842). The company, previously known as Bontan Corp Inc and Dealcheck Com Inc, is incorporated in the British Virgin Islands and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates ongoing corporate actions related to the company's registration statements, which could impact the availability or terms of securities offered under those statements.
Risk Assessment
Risk Level: low — This is a routine filing related to a registration statement and does not appear to contain new material financial or operational information.
Key Numbers
- 001-40086 — SEC File Number (Identifies the company's filing with the SEC.)
- 333-275842 — Form S-8 File Number (This 6-K is incorporated by reference into this registration statement.)
Key Players & Entities
- Portage Biotech Inc. (company) — Filer
- 001-40086 (company) — SEC File Number
- 333-275842 (company) — Form S-8 File Number
- Bontan Corp Inc (company) — Former Company Name
- Dealcheck Com Inc (company) — Former Company Name
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is being filed to be incorporated by reference into Portage Biotech Inc.'s registration statement on Form S-8 (File No. 333-275842).
What is Portage Biotech Inc.'s SEC File Number?
Portage Biotech Inc.'s SEC File Number is 001-40086.
What is the company's principal executive office address?
The company's principal executive office is located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110.
Has Portage Biotech Inc. changed its name previously?
Yes, the company was formerly known as Bontan Corp Inc (name change on April 21, 2003) and Dealcheck Com Inc (name change on September 21, 1999).
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-01-06 06:00:42
Filing Documents
- f6k_010625.htm (6-K) — 8KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-000032.txt ( ) — 16KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. On January 6, 2025, Portage Biotech Inc. issued a press release announcing the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists and the appointment of Peter Molloy as Chief Executive Officer of the subsidiary, to be named Cyncado Therapeutics TM , Inc. A copy of the press release is filed herewith as Exhibit 99.1. Exhibits Exhibit Number Description 99.1 Press Release dated January 6, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 6, 2025 PORTAGE BIOTECH INC. By: /s/ Andrea Park Andrea Park Chief Financial Officer